← Leaderboards
Awewura Jacob Kwara
Miriam Hospital
$10,757,383
Attributed
$10,757,383
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $961.6K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,757,383 · 7
By mechanism
R01$7,326,414 · 2
D43$1,491,130 · 1
R21$817,265 · 2
K23$634,770 · 1
R56$487,804 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDrug KineticsDoseCessation Of LifePersonsAffectTuberculosisGhanaDrug InteractionsProgramsCo-InfectionAnti-Retroviral AgentsAfricanTuberculosis TreatmentRifampinAfricaBaseInnovationPharmacologyMorbidity - Disease RateAdultChildEfavirenzRegimen
Grant awards (29)
Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents$466,515
R01 · FY2025 · AI · contact PI
Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents$201,741
R01 · FY2025 · AI · contact PI
Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents$690,567
R01 · FY2024 · AI · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$633,564
R01 · FY2022 · HD · contact PI
Pharmacokinetics and Pharmacodynamics of Dolutegravir in Children Weighing â¥20 Kg Living with HIV with and without TB Coinfection$206,434
R21 · FY2022 · AI · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$597,608
R01 · FY2021 · HD · contact PI
Adherence and Intracellular Pharmacology of Tenofovir and HBV Suppression in People with HBV/HIV Coinfection$185,275
R21 · FY2021 · AI · contact PI
Pharmacokinetics and Pharmacodynamics of Dolutegravir in Children Weighing â¥20 Kg Living with HIV with and without TB Coinfection$178,764
R21 · FY2021 · AI · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$611,522
R01 · FY2020 · HD · contact PI
Adherence and Intracellular Pharmacology of Tenofovir and HBV Suppression in People with HBV/HIV Coinfection$246,792
R21 · FY2020 · AI · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$623,600
R01 · FY2019 · HD · contact PI
Training Program in Tuberculosis and HIV Research in Ghana$298,356
D43 · FY2019 · TW · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$660,869
R01 · FY2018 · HD · contact PI
Training Program in Tuberculosis and HIV Research in Ghana$297,034
D43 · FY2018 · TW · contact PI
Training Program in Tuberculosis and HIV Research in Ghana$298,412
D43 · FY2017 · TW · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$586,616
R01 · FY2016 · HD · contact PI
Training Program in Tuberculosis and HIV Research in Ghana$298,057
D43 · FY2016 · TW · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$36,020
R01 · FY2016 · HD · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$533,287
R01 · FY2015 · HD · contact PI
Training Program in Tuberculosis and HIV Research in Ghana$299,271
D43 · FY2015 · TW · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$543,018
R01 · FY2014 · HD · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$538,429
R01 · FY2013 · HD · contact PI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children$603,058
R01 · FY2012 · HD · contact PI
Pharmacogenetics and Drug-Drug Interactions during HIV/TB Therapy$487,804
R56 · FY2011 · AI · contact PI
Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions$126,954
K23 · FY2010 · AI · contact PI
Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions$126,954
K23 · FY2009 · AI · contact PI
Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions$126,954
K23 · FY2008 · AI · contact PI
Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions$126,954
K23 · FY2007 · AI · contact PI
Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions$126,954
K23 · FY2006 · AI · contact PI